Simulation of lipid-lowering therapy (LLT) intensification in very high-risk patients with atherosclerotic cardiovascular disease

•Simulation modeling assessed LDL-C goal attainment in very high-risk ASCVD patients.•Most patients (99.1%) were estimated to achieve LDL-C

Saved in:
Bibliographic Details
Published in:Journal of clinical lipidology 2022-11, Vol.16 (6), p.901-905
Main Authors: Gu, Jing, Sanchez, Robert J, Chauhan, Ankita, Fazio, Sergio, Rosenson, Robert S
Format: Article
Language:English
Subjects:
Anticholesteremic Agents - therapeutic use
ASCVD
Atherosclerosis - drug therapy
Cardiovascular Diseases - drug therapy
Cholesterol, LDL
Evinacumab
Ezetimibe - therapeutic use
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
LDL-C
Lipid-lowering therapies
PCSK9 Inhibitors
Proprotein Convertase 9
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Simulation modeling assessed LDL-C goal attainment in very high-risk ASCVD patients.•Most patients (99.1%) were estimated to achieve LDL-C
ISSN:1933-2874
1876-4789
DOI:10.1016/j.jacl.2022.10.001